nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—Allograft Rejection—C4A—multiple sclerosis	0.0186	0.0327	CbGpPWpGaD
Azilsartan medoxomil—Hyperuricaemia—Cladribine—multiple sclerosis	0.0161	0.0375	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR1—multiple sclerosis	0.016	0.0281	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Cladribine—multiple sclerosis	0.0152	0.0355	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL13—multiple sclerosis	0.0152	0.0266	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL12A—multiple sclerosis	0.0152	0.0266	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.0138	0.0242	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ITGA4—multiple sclerosis	0.0138	0.0242	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Fingolimod—multiple sclerosis	0.013	0.0303	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FOXP3—multiple sclerosis	0.013	0.0229	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Fingolimod—multiple sclerosis	0.012	0.028	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-G—multiple sclerosis	0.0118	0.0208	CbGpPWpGaD
Azilsartan medoxomil—Hyperuricaemia—Mitoxantrone—multiple sclerosis	0.0106	0.0247	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CXCR3—multiple sclerosis	0.0106	0.0186	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR2—multiple sclerosis	0.0103	0.0181	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL17A—multiple sclerosis	0.0103	0.018	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Mitoxantrone—multiple sclerosis	0.01	0.0233	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD28—multiple sclerosis	0.00997	0.0175	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00976	0.0227	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—TGFB1—multiple sclerosis	0.00972	0.017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL12B—multiple sclerosis	0.00954	0.0167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.00946	0.0166	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Fingolimod—multiple sclerosis	0.00924	0.0215	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Fingolimod—multiple sclerosis	0.00915	0.0213	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD40—multiple sclerosis	0.0091	0.016	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CTLA4—multiple sclerosis	0.00897	0.0157	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GPR65—multiple sclerosis	0.00834	0.0146	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00814	0.0189	CcSEcCtD
Azilsartan medoxomil—Fatigue—Fingolimod—multiple sclerosis	0.00813	0.0189	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.0079	0.0139	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.00753	0.0132	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.00753	0.0132	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.00746	0.0131	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Cladribine—multiple sclerosis	0.00741	0.0172	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Cladribine—multiple sclerosis	0.00739	0.0172	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.00739	0.013	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD86—multiple sclerosis	0.00711	0.0125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD40LG—multiple sclerosis	0.00697	0.0122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—multiple sclerosis	0.00697	0.0122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.00685	0.012	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Cladribine—multiple sclerosis	0.00682	0.0159	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL4—multiple sclerosis	0.00678	0.0119	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Fingolimod—multiple sclerosis	0.00676	0.0157	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.00669	0.0156	CcSEcCtD
Azilsartan medoxomil—Pruritus—Fingolimod—multiple sclerosis	0.00667	0.0155	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCR5—multiple sclerosis	0.00665	0.0117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-B—multiple sclerosis	0.00663	0.0116	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Fingolimod—multiple sclerosis	0.00645	0.015	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.00644	0.0113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FAS—multiple sclerosis	0.00625	0.011	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Fingolimod—multiple sclerosis	0.00623	0.0145	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2RA—multiple sclerosis	0.00622	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-A—multiple sclerosis	0.00615	0.0108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.00589	0.0103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.00562	0.00985	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00553	0.0129	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.00552	0.00968	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.00536	0.00941	CbGpPWpGaD
Azilsartan medoxomil—Hyperuricaemia—Methotrexate—multiple sclerosis	0.00529	0.0123	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Cladribine—multiple sclerosis	0.00524	0.0122	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—S1PR1—multiple sclerosis	0.00522	0.00915	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Cladribine—multiple sclerosis	0.00519	0.0121	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD80—multiple sclerosis	0.00519	0.0091	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00505	0.00886	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00505	0.00886	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Methotrexate—multiple sclerosis	0.00499	0.0116	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.00499	0.00875	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00485	0.00851	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00461	0.0107	CcSEcCtD
Azilsartan medoxomil—Fatigue—Cladribine—multiple sclerosis	0.00461	0.0107	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.0045	0.0105	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Azathioprine—multiple sclerosis	0.00422	0.00981	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GPR65—multiple sclerosis	0.0042	0.00737	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IFNG—multiple sclerosis	0.0041	0.00719	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00404	0.00709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00403	0.00707	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—multiple sclerosis	0.00402	0.00705	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.0039	0.00685	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR1—multiple sclerosis	0.00385	0.00674	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL13—multiple sclerosis	0.00385	0.00674	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Cladribine—multiple sclerosis	0.00383	0.00892	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—multiple sclerosis	0.00383	0.00671	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.0038	0.00666	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Cladribine—multiple sclerosis	0.00378	0.00879	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00375	0.00872	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—multiple sclerosis	0.00366	0.00642	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00366	0.0085	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Cladribine—multiple sclerosis	0.00366	0.0085	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—multiple sclerosis	0.00364	0.00639	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.0036	0.00631	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Cladribine—multiple sclerosis	0.00353	0.00822	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.0035	0.00615	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00347	0.00609	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00346	0.00607	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Mitoxantrone—multiple sclerosis	0.00341	0.00793	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Methylprednisolone—multiple sclerosis	0.00338	0.00785	CcSEcCtD
Azilsartan medoxomil—Rash—Cladribine—multiple sclerosis	0.00337	0.00783	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Cladribine—multiple sclerosis	0.00337	0.00783	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00334	0.00587	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00325	0.00571	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Prednisolone—multiple sclerosis	0.00323	0.0075	CcSEcCtD
Azilsartan medoxomil—Nausea—Cladribine—multiple sclerosis	0.00317	0.00738	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.00313	0.00548	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Betamethasone—multiple sclerosis	0.00307	0.00714	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Dexamethasone—multiple sclerosis	0.00307	0.00714	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mitoxantrone—multiple sclerosis	0.00303	0.00704	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.003	0.00527	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Azathioprine—multiple sclerosis	0.00297	0.00691	CcSEcCtD
Azilsartan medoxomil—Angioedema—Triamcinolone—multiple sclerosis	0.00297	0.0069	CcSEcCtD
Azilsartan medoxomil—Angioedema—Methylprednisolone—multiple sclerosis	0.00296	0.00688	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00295	0.00517	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Prednisone—multiple sclerosis	0.0029	0.00674	CcSEcCtD
Azilsartan medoxomil—Dizziness—Azathioprine—multiple sclerosis	0.00287	0.00668	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—multiple sclerosis	0.00284	0.00499	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL3—multiple sclerosis	0.00274	0.00481	CbGpPWpGaD
Azilsartan medoxomil—Rash—Azathioprine—multiple sclerosis	0.00274	0.00637	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00274	0.00637	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Azathioprine—multiple sclerosis	0.00274	0.00636	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.0027	0.00474	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Dexamethasone—multiple sclerosis	0.00269	0.00626	CcSEcCtD
Azilsartan medoxomil—Angioedema—Betamethasone—multiple sclerosis	0.00269	0.00626	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.00268	0.00469	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Prednisone—multiple sclerosis	0.00267	0.00622	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—multiple sclerosis	0.00265	0.00466	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.00264	0.00463	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00259	0.00603	CcSEcCtD
Azilsartan medoxomil—Nausea—Azathioprine—multiple sclerosis	0.00258	0.006	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methylprednisolone—multiple sclerosis	0.00257	0.00597	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.00255	0.00447	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Mitoxantrone—multiple sclerosis	0.00252	0.00586	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.00251	0.0044	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR2—multiple sclerosis	0.00248	0.00435	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.00245	0.00429	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.00244	0.00429	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Mitoxantrone—multiple sclerosis	0.0024	0.00559	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.00239	0.00419	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.00238	0.00417	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Betamethasone—multiple sclerosis	0.00236	0.00548	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00236	0.00548	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisone—multiple sclerosis	0.00234	0.00545	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.00233	0.00408	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR1—multiple sclerosis	0.00229	0.00401	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Triamcinolone—multiple sclerosis	0.00228	0.00531	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methylprednisolone—multiple sclerosis	0.00228	0.0053	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RGS1—multiple sclerosis	0.00228	0.00399	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Methotrexate—multiple sclerosis	0.00223	0.0052	CcSEcCtD
Azilsartan medoxomil—Rash—Mitoxantrone—multiple sclerosis	0.00221	0.00515	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mitoxantrone—multiple sclerosis	0.00221	0.00515	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00217	0.00381	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR1—multiple sclerosis	0.00217	0.00381	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00217	0.00504	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GPR65—multiple sclerosis	0.00216	0.00378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.0021	0.00368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LINGO1—multiple sclerosis	0.00209	0.00366	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Mitoxantrone—multiple sclerosis	0.00209	0.00485	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00208	0.00483	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00208	0.00483	CcSEcCtD
Azilsartan medoxomil—Fatigue—Betamethasone—multiple sclerosis	0.00207	0.00482	CcSEcCtD
Azilsartan medoxomil—Fatigue—Dexamethasone—multiple sclerosis	0.00207	0.00482	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.00206	0.00361	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Prednisone—multiple sclerosis	0.00205	0.00478	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Prednisone—multiple sclerosis	0.00203	0.00473	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.00197	0.00346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR1—multiple sclerosis	0.00197	0.00346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.00197	0.00345	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisolone—multiple sclerosis	0.00191	0.00443	CcSEcCtD
Azilsartan medoxomil—Asthenia—Triamcinolone—multiple sclerosis	0.0019	0.00442	CcSEcCtD
Azilsartan medoxomil—Asthenia—Methylprednisolone—multiple sclerosis	0.0019	0.00441	CcSEcCtD
Azilsartan medoxomil—Pruritus—Triamcinolone—multiple sclerosis	0.00187	0.00436	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methylprednisolone—multiple sclerosis	0.00187	0.00435	CcSEcCtD
Azilsartan medoxomil—Rash—Prednisolone—multiple sclerosis	0.00182	0.00423	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisolone—multiple sclerosis	0.00181	0.00422	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00181	0.00422	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TAGAP—multiple sclerosis	0.00181	0.00317	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00181	0.00421	CcSEcCtD
Azilsartan medoxomil—Fatigue—Prednisone—multiple sclerosis	0.0018	0.0042	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL5—multiple sclerosis	0.00177	0.00311	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Triamcinolone—multiple sclerosis	0.00175	0.00408	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methylprednisolone—multiple sclerosis	0.00175	0.00407	CcSEcCtD
Azilsartan medoxomil—Asthenia—Betamethasone—multiple sclerosis	0.00172	0.00401	CcSEcCtD
Azilsartan medoxomil—Asthenia—Dexamethasone—multiple sclerosis	0.00172	0.00401	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—multiple sclerosis	0.00172	0.00399	CcSEcCtD
Azilsartan medoxomil—Nausea—Prednisolone—multiple sclerosis	0.00171	0.00398	CcSEcCtD
Azilsartan medoxomil—Pruritus—Betamethasone—multiple sclerosis	0.0017	0.00396	CcSEcCtD
Azilsartan medoxomil—Pruritus—Dexamethasone—multiple sclerosis	0.0017	0.00396	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—multiple sclerosis	0.0017	0.00395	CcSEcCtD
Azilsartan medoxomil—Rash—Triamcinolone—multiple sclerosis	0.00167	0.00389	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Triamcinolone—multiple sclerosis	0.00167	0.00388	CcSEcCtD
Azilsartan medoxomil—Rash—Methylprednisolone—multiple sclerosis	0.00167	0.00388	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methylprednisolone—multiple sclerosis	0.00167	0.00387	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Dexamethasone—multiple sclerosis	0.00164	0.00383	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Betamethasone—multiple sclerosis	0.00164	0.00383	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.00164	0.00287	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.0016	0.00281	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR5—multiple sclerosis	0.0016	0.0028	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Betamethasone—multiple sclerosis	0.00159	0.0037	CcSEcCtD
Azilsartan medoxomil—Dizziness—Dexamethasone—multiple sclerosis	0.00159	0.0037	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—S1PR1—multiple sclerosis	0.00158	0.00277	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Triamcinolone—multiple sclerosis	0.00157	0.00366	CcSEcCtD
Azilsartan medoxomil—Nausea—Methylprednisolone—multiple sclerosis	0.00157	0.00365	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GPC5—multiple sclerosis	0.00154	0.0027	CbGpPWpGaD
Azilsartan medoxomil—Rash—Dexamethasone—multiple sclerosis	0.00152	0.00353	CcSEcCtD
Azilsartan medoxomil—Rash—Betamethasone—multiple sclerosis	0.00152	0.00353	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Dexamethasone—multiple sclerosis	0.00151	0.00352	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Betamethasone—multiple sclerosis	0.00151	0.00352	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00151	0.00351	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—multiple sclerosis	0.00151	0.00351	CcSEcCtD
Azilsartan medoxomil—Asthenia—Prednisone—multiple sclerosis	0.0015	0.00349	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.00149	0.00261	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Prednisone—multiple sclerosis	0.00148	0.00345	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00144	0.00252	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Prednisone—multiple sclerosis	0.00143	0.00333	CcSEcCtD
Azilsartan medoxomil—Nausea—Betamethasone—multiple sclerosis	0.00143	0.00332	CcSEcCtD
Azilsartan medoxomil—Nausea—Dexamethasone—multiple sclerosis	0.00143	0.00332	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL3—multiple sclerosis	0.00141	0.00247	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR2—multiple sclerosis	0.0014	0.00246	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisone—multiple sclerosis	0.00138	0.00322	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTGER4—multiple sclerosis	0.00135	0.00237	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RGS1—multiple sclerosis	0.00134	0.00236	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisone—multiple sclerosis	0.00132	0.00307	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisone—multiple sclerosis	0.00132	0.00307	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR3—multiple sclerosis	0.00131	0.00229	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR1—multiple sclerosis	0.00129	0.00227	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GPR65—multiple sclerosis	0.00127	0.00224	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR2—multiple sclerosis	0.00127	0.00223	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Methotrexate—multiple sclerosis	0.00126	0.00292	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.00125	0.0022	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—POMC—multiple sclerosis	0.00125	0.00219	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Prednisone—multiple sclerosis	0.00124	0.00289	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methotrexate—multiple sclerosis	0.00124	0.00288	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL2—multiple sclerosis	0.00122	0.00214	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Methotrexate—multiple sclerosis	0.0012	0.00278	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR1—multiple sclerosis	0.00117	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL13—multiple sclerosis	0.00117	0.00204	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR1—multiple sclerosis	0.00117	0.00204	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.00116	0.00204	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Methotrexate—multiple sclerosis	0.00116	0.00269	CcSEcCtD
Azilsartan medoxomil—Rash—Methotrexate—multiple sclerosis	0.0011	0.00257	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—multiple sclerosis	0.0011	0.00256	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL10—multiple sclerosis	0.00106	0.00185	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Methotrexate—multiple sclerosis	0.00104	0.00242	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL5—multiple sclerosis	0.001	0.00176	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000962	0.00169	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL5—multiple sclerosis	0.00091	0.0016	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000902	0.00158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000889	0.00156	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL3—multiple sclerosis	0.000831	0.00146	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR5—multiple sclerosis	0.000819	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000808	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTGER4—multiple sclerosis	0.0008	0.0014	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PGR—multiple sclerosis	0.000787	0.00138	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR3—multiple sclerosis	0.000772	0.00135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD28—multiple sclerosis	0.000765	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR2—multiple sclerosis	0.000751	0.00132	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—POMC—multiple sclerosis	0.000705	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR1—multiple sclerosis	0.000693	0.00122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—POMC—multiple sclerosis	0.00064	0.00112	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL2—multiple sclerosis	0.000627	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL10—multiple sclerosis	0.000624	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TYK2—multiple sclerosis	0.000569	0.000998	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD86—multiple sclerosis	0.000546	0.000957	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL5—multiple sclerosis	0.000537	0.000942	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—multiple sclerosis	0.000521	0.000914	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPP1—multiple sclerosis	0.000498	0.000873	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR5—multiple sclerosis	0.000484	0.000849	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2RA—multiple sclerosis	0.000477	0.000837	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—multiple sclerosis	0.000473	0.00083	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOE—multiple sclerosis	0.00044	0.000772	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD80—multiple sclerosis	0.000398	0.000698	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—POMC—multiple sclerosis	0.000378	0.000664	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL2—multiple sclerosis	0.00037	0.000649	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK1—multiple sclerosis	0.000362	0.000635	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TYK2—multiple sclerosis	0.000336	0.00059	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—multiple sclerosis	0.00028	0.000491	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—multiple sclerosis	0.000278	0.000488	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—multiple sclerosis	0.000265	0.000464	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—multiple sclerosis	0.000235	0.000413	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—multiple sclerosis	0.000219	0.000384	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—multiple sclerosis	0.000218	0.000383	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK1—multiple sclerosis	0.000214	0.000375	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—multiple sclerosis	0.000164	0.000288	CbGpPWpGaD
